| Subject: | FDA Issues Class I Recall Of The Innervision Snap Shunt Ventricular Catheter, BioGlide and Snap Shunt Ventricular Catheter, Bioglide |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Sat, 28 Mar 2009 - 06:00 am |
| The Food and Drug Administration (FDA) and Medtronic have notified healthcare professionals about a Class I Recall of the Innervision Snap Shunt Ventricular Catheter, BioGlide and Snap Shunt Ventricular Catheter, BioGlide due to the possibility that the ventricular catheter may become detached from the snap base assembly after implantation and may require emergency corrective surgery. The recalled product was distributed from April 29, 2004 through December 12, 2008. Patients with questions... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
